Effect of clozapine and other antipsychotics on the level of platelet-associated autoantibodies in children with schizophrenia: A longitudinal follow-up study

Tanya Ebert, Mila Schechtman, Yael Midbari, Avraham Weizman, Meir Shinitzky, Boris Spivak

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Previous studies have demonstrated significantly higher blood titers of platelet-associated autoantibodies (PAA) in adult schizophrenia patients compared to normal healthy subjects. In addition, young adult schizophrenia patients at their early stages of the disorder displayed higher PAA titers than older patients with longer duration of the disorder. Aim: To assess longitudinally the blood titers of PAA in inpatients with childhood-onset schizophrenia at admission, after short- and long-term follow-up, and the correlation of these titers with the response to clozapine and other antipsychotic treatments. Methods: Thirty children, age range of 6-12 (mean ± SD: 9.6 ± 1.5 years), with DSM-IV TR schizophrenia in active psychotic state were assessed 3 times: at baseline, after short-term (8-17 weeks; n = 26) and after long-term follow-up (33-170 weeks; n = 19). The blood titers of PAA were analyzed using ELISA and expressed by a linear optical density (OD) scale. A test recording >1.4 OD units was predefined as the positive cutoff value. Results: On long-term follow-up, 9 out of the 17 children who were PAA-positive at baseline became PAA-negative: 7 already after 2 months of clozapine treatment and 2 following 3 years of risperidone treatment. Eight children remained PAA-positive during the entire study period. There was no significant correlation between the clinical improvement (as assessed by change in the Positive and Negative Syndrome Scale score) and the alteration in PAA levels (n = 19, r = -0.4, p = 0.088). Conclusions: High rates of positive PAA in COS patients may indicate an active autoimmune process in early-onset schizophrenia. It is concluded that PAA may serve as a biomarker for the diagnosis of COS, but does not predict the response to treatment. A transition to a PAA-negative status does not indicate an improvement in psychosis.

Original languageEnglish
Pages (from-to)120-124
Number of pages5
JournalNeuropsychobiology
Volume71
Issue number2
DOIs
StatePublished - 6 May 2015

Keywords

  • Biomarker
  • Childhood-onset schizophrenia
  • Immune system
  • Platelet-associated autoantibodies
  • Schizophrenia

Fingerprint

Dive into the research topics of 'Effect of clozapine and other antipsychotics on the level of platelet-associated autoantibodies in children with schizophrenia: A longitudinal follow-up study'. Together they form a unique fingerprint.

Cite this